Low-dose desmopressin effective for nocturia

August 19, 2013
Low-dose desmopressin effective for nocturia
Desmopressin orally disintegrating tablets are effective and well-tolerated for nocturia among women and men at doses of 25 and 50 µg per day, respectively, according to two studies published in the September issue of The Journal of Urology.

(HealthDay)—Desmopressin orally disintegrating tablets are effective and well-tolerated for nocturia among women and men at doses of 25 and 50 µg per day, respectively, according to two studies published in the September issue of The Journal of Urology.

Peter K. Sand, M.D., from the Northshore University HealthSystem in Evanston, Ill., and colleagues conducted a three-month randomized trial to compare 25 µg desmopressin once daily with in 261 women (aged 19 to 87 years) with nocturia (two or more nocturnal voids). The researchers found that desmopressin correlated with a significant reduction in the mean number of nocturnal voids and with increased odds of a 33 percent or greater response versus placebo during three months (odds ratio, 1.85). At three months, desmopressin correlated with significantly increased time to first nocturnal void by 49 minutes compared with placebo. Desmopressin was well-tolerated and linked to significant increases in health related and sleep quality versus placebo.

Jeffrey P. Weiss, M.D., from the SUNY Downstate College of Medicine in Brooklyn, N.Y., and colleagues conducted a three-month randomized trial comparing 50 and 75 µg desmopressin with placebo among 385 men (aged 20 to 87 years) with nocturia. The researchers found that desmopressin correlated with significantly reduced number of nocturnal voids and with increased odds of a 33 percent or greater response (odds ratios, 1.98 and 2.04 for 50 and 75 µg, respectively). The time to first void increased significantly by about 40 minutes from baseline with 50 and 75 µg desmopressin versus placebo.

"In summary, nocturia is a rather simple symptom that is rather complicated to manage. The etiology is often multifactorial and many patients defy categorization," writes the author of an accompanying editorial. "Desmopressin represents a unique but carries the potential for a severe complication (hyponatremia). Gender specific dosing appears to decrease this risk but monitoring serum sodium levels is still indicated."

Several authors from both studies disclosed financial ties to pharmaceutical companies, including Ferring, which supported the studies and manufactures desmopressin.

Explore further: Dexamethasone beats placebo for cancer-related fatigue

More information: Abstract - Sand
Full Text
Abstract - Weiss
Full Text
Editorial (subscription or payment may be required)

Related Stories

Dexamethasone beats placebo for cancer-related fatigue

August 1, 2013
(HealthDay)—For patients with advanced cancer, dexamethasone is better than placebo for reducing cancer-related fatigue (CRF), according to a study published online July 29 in the Journal of Clinical Oncology.

Tadalafil effective, safe in complete erectile dysfunction

October 14, 2012
(HealthDay)—In men with complete erectile dysfunction (ED), tadalafil 2.5 and 5 mg once-daily result an in intercourse success rate of 32.4 and 46.4 percent, respectively, according to research published online Oct. 4 in ...

Sumatriptan/Naproxen helpful in treating teens' migraines

May 15, 2012
(HealthDay) -- Treatment with sumatriptan and naproxen sodium (suma/nap) is well tolerated and effective in reducing migraine pain in adolescents, according to a study published online May 14 in Pediatrics.

Ambrisentan not effective in idiopathic pulmonary fibrosis

May 7, 2013
(HealthDay)—The endothelin A receptor-selective antagonist ambrisentan is not effective for reducing the rate of idiopathic pulmonary fibrosis (IPF) progression, according to a study published in the May 7 issue of the ...

Fidaxomicin ups outcome of C. difficile-tied diarrhea in cancer

June 10, 2013
(HealthDay)—For patients with cancer with Clostridium difficile-associated diarrhea (CDAD), fidaxomicin treatment is associated with improved outcomes compared with vancomycin treatment, according to research published ...

Semagacestat doesn't improve cognitive status in Alzheimer's

July 25, 2013
(HealthDay)—For patients with Alzheimer's disease, treatment with the small-molecule γ-secretase inhibitor semagacestat does not improve cognitive status and is associated with worsening of cognitive function, according ...

Recommended for you

Google searches can be used to track dengue in underdeveloped countries

July 20, 2017
An analytical tool that combines Google search data with government-provided clinical data can quickly and accurately track dengue fever in less-developed countries, according to new research published in PLOS Computational ...

MRSA emerged years before methicillin was even discovered

July 19, 2017
Methicillin resistant Staphylococcus aureus (MRSA) emerged long before the introduction of the antibiotic methicillin into clinical practice, according to a study published in the open access journal Genome Biology. It was ...

New test distinguishes Zika from similar viral infections

July 18, 2017
A new test is the best-to-date in differentiating Zika virus infections from infections caused by similar viruses. The antibody-based assay, developed by researchers at UC Berkeley and Humabs BioMed, a private biotechnology ...

'Superbugs' study reveals complex picture of E. coli bloodstream infections

July 18, 2017
The first large-scale genetic study of Escherichia coli (E. coli) cultured from patients with bloodstream infections in England showed that drug resistant 'superbugs' are not always out-competing other strains. Research by ...

Ebola virus can persist in monkeys that survived disease, even after symptoms disappear

July 17, 2017
Ebola virus infection can be detected in rhesus monkeys that survive the disease and no longer show symptoms, according to research published by Army scientists in today's online edition of the journal Nature Microbiology. ...

Mountain gorillas have herpes virus similar to that found in humans

July 13, 2017
Scientists from the University of California, Davis, have detected a herpes virus in wild mountain gorillas that is very similar to the Epstein-Barr virus in humans, according to a study published today in the journal Scientific ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.